Skip to main content
. 2024 Jul 24;42(30):3561–3569. doi: 10.1200/JCO.23.01995

FIG 2.

FIG 2.

Prediction of ELT benefit by MP based on DR. K-M analysis of risk of DR comparing extended letrozole versus placebo in patients with (A) MP low-risk (n = 1,160) tumors and patients with (B) MP high-risk (n = 706) tumors. DR, distant recurrence; ELT, extended letrozole therapy; HR, hazard ratio; K-M, Kaplan-Meier; MP, MammaPrint.